Opko Health CEO Phillip Md Et Al Frost Purchases 51,000 Shares (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 51,000 shares of the stock on the open market in a transaction dated Thursday, April 17th. The stock was purchased at an average cost of $8.15 per share, for a total transaction of $415,650.00. Following the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $16,198,125. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Oppenheimer initiated coverage on shares of Opko Health in a research note on Thursday, March 13th. They set an “outperform” rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $12.83.
Shares of Opko Health (NYSE:OPK) remained flat at $8.14 during during mid-day trading trading on Monday. 278,964 shares of the company’s stock traded hands. Opko Health has a one year low of $6.14 and a one year high of $12.95. The stock’s 50-day moving average is $9.24 and its 200-day moving average is $9.40. The company’s market cap is $3.361 billion.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.05) by $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. The company’s quarterly revenue was up 27.8% on a year-over-year basis. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.
OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national pharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.